Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Xellia Pharmaceuticals
Xellia Pharmaceuticals
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Manufacturing
Xellia Cleveland manufacturing facility operational for anti-infectives
In addition to commencing commercial supply, the facility is also preparing ramp-up of its recently installed aseptic bag manufacturing line
Ingredients
Xellia Pharmaceuticals launches additional Vanco Ready doses
Vanco Ready will now cover relevant doses from 500 mg to 2 g in 250 mg increments
Regulatory
Xellia Pharmaceuticals expands approved doses of VANCO READYTM
The drug is universally recognised as a key intervention in the management of sepsi at life-threatening state, as well as other infections
Recruitment
Career Opportunities: Automation Engineer (7243)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Global Packaging Manager, Sterile Products (5677)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Senior Logistics and Process Engineer (6982)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Subscribe now